Valuation: TScan Therapeutics, Inc.

Market Cap 63.31M 55.51M 51.17M 47.9M 89.83M 5.97B 91.69M 615M 238M 2.95B 238M 233M 10.24B P/E 2026 *
-1.11x
P/E 2027 * -1.05x
Enterprise Value -35.56M -31.17M -28.74M -26.9M -50.45M -3.35B -51.49M -345M -134M -1.66B -134M -131M -5.75B EV / Sales 2026 *
-4.7x
EV / Sales 2027 * -1.47x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-27 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-19 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-07 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
11-14 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
11-12 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-12 TScan Therapeutics Q3 revenue jumps RE
1 day+15.33%
1 week+5.30%
Current month-10.30%
1 month-9.46%
3 months-5.94%
6 months-8.60%
Current year-3.12%
1 week 0.83
Extreme 0.8251
0.97
1 month 0.83
Extreme 0.8251
1.11
Current year 0.83
Extreme 0.8251
1.47
1 year 0.83
Extreme 0.8251
2.57
3 years 0.83
Extreme 0.8251
9.69
5 years 0.83
Extreme 0.8251
14.71
10 years 0.83
Extreme 0.8251
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer 50 08/04/2024
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

67,000 0.1200%
05-20
Baker Bros. Advisors LP
FreeCompany 134,000 0.2400%
05-20Free

Director

67,000 0.1200%
Change 5-day change 1-year change 3-year change Capi.($)
+15.33%+5.30%-34.54%-63.30% 63.31M
+0.33%+1.37%+64.03%+119.11% 55.63B
+0.82%+15.05%+79.93%+84.34% 52.25B
+1.36%+0.36%-14.06%-14.69% 23.07B
-1.04%+7.91%+1.61%+419.24% 22.41B
-0.18%+7.20%+32.16%-14.07% 17.32B
-1.10%+4.00%+28.70%-34.51% 15.94B
-3.35%+8.96%+132.20%+290.18% 13.47B
+2.89%+5.51%+27.11%+181.45% 13.77B
+1.31%+0.53%+28.62% - 12.43B
Average +1.64%+4.83%+34.58%+107.53% 22.64B
Weighted average by Cap. +0.27%+5.13%+48.47%+120.12%

Financials

2026 *2027 *
Net sales 7.56M 6.63M 6.11M 5.72M 10.72M 713M 10.95M 73.41M 28.41M 352M 28.38M 27.76M 1.22B 7.81M 6.85M 6.31M 5.91M 11.08M 736M 11.31M 75.84M 29.35M 364M 29.32M 28.68M 1.26B
Net income -115M -101M -93M -87.07M -163M -10.85B -167M -1.12B -433M -5.36B -432M -423M -18.6B -125M -109M -101M -94.44M -177M -11.77B -181M -1.21B -469M -5.82B -469M -458M -20.18B
Net Debt -98.87M -86.69M -79.91M -74.81M -140M -9.33B -143M -960M -372M -4.61B -371M -363M -15.98B -74.76M -65.55M -60.42M -56.56M -106M -7.05B -108M -726M -281M -3.49B -281M -275M -12.09B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
26/06/26 $0.9688 +15.33% 713,271
25/06/26 $0.8400 -4.64% 647,370
24/06/26 $0.8809 -4.35% 452,195
23/06/26 $0.9210 +6.46% 513,421
22/06/26 $0.8651 -5.97% 1,617,984
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.9688USD
Average target price
6.000USD
Spread / Average Target
+519.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock